The effects of cannabidiol against Methotrexate‐induced lung damage
Basic & Clinical Pharmacology & Toxicology · 2024-05 · 134 (5) · 695-703
DOI: 10.1111/bcpt.13992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 22.02.2024. Verfasst von Ozlem Ozmen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Veterinary Medicine, Department of Pathology, Burdur Mehmet Akif Ersoy University, Burdur, Turkey. Hauptthemen laut MEDLINE: Methotrexate, Cannabidiol. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Suleyman Demirel University.
Abstract (Originalsprache)
Methotrexate (MTX) is a widely used medication for various cancers, yet its use is associated with adverse effects on organs, notably the lungs. Cannabidiol (CBD), known for its antioxidant and anti‐inflammatory properties, was investigated for its potential protective effects against MTX‐induced lung injury. Thirty‐two female Wistar Albino rats were divided into four groups: control, MTX (single 20 mg/kg intraperitoneal dose), MTX + CBD (single 20 mg/kg MTX with 0.1 ml of 5 mg/kg CBD for 7 days intraperitoneally) and CBD only (for 7 days). Lung tissues were analysed using histopathological, immunohistochemical and PCR methods after the study. Histopathological assessment of the MTX group revealed lung lesions like hyperemia, edema, inflammatory cell infiltration and epithelial cell loss. Immunohistochemical examination showed significant increases in Cas‐3, tumour necrosis factor‐alpha (TNF‐α) and nuclear factor‐kappa B (NF‐κB) expressions. PCR analysis indicated elevated expressions of apoptotic peptidase activating factor 1 (Apaf 1), glucose‐regulated protein 78 (GRP 78), CCAAT‐enhancer‐binding protein homologous protein (CHOP) and cytochrome C (Cyt C), along with reduced B‐cell lymphoma‐2 (BCL 2) expressions in the MTX group, though not statistically significant. Remarkably, CBD treatment reversed these findings. This study highlights CBD's potential in mitigating MTX‐induced lung damage, suggesting its therapeutic promise.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Veterinary Medicine, Department of Pathology, Burdur Mehmet Akif Ersoy University, Burdur, Turkey.
- Faculty of Medicine, Department of Medical Biology, Suleyman Demirel University, Isparta, Turkey.
- Faculty of Medicine, Department of Medical Pharmacology, Suleyman Demirel University, Isparta, Turkey.
ORCID-Profile: Ozlem Ozmen, Adem Milletsever, Serife Tasan, Esma Selcuk, Mehtap Savran
Förderung
- Suleyman Demirel University
Zitieren
APA
Ozmen, O., Milletsever, A., Tasan, S., Selcuk, E., & Savran, M. (2024). The effects of cannabidiol against Methotrexate‐induced lung damage. Basic & Clinical Pharmacology & Toxicology, 134(5), 695-703. https://doi.org/10.1111/bcpt.13992
Vancouver
Ozmen O, Milletsever A, Tasan S, Selcuk E, Savran M. The effects of cannabidiol against Methotrexate‐induced lung damage. Basic & Clinical Pharmacology & Toxicology. 2024;134(5):695-703. doi:10.1111/bcpt.13992
BibTeX
@article{Ozmen2024,
author = {Ozmen, Ozlem and Milletsever, Adem and Tasan, Serife and Selcuk, Esma and Savran, Mehtap},
title = {The effects of cannabidiol against Methotrexate‐induced lung damage},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
volume = {134},
number = {5},
pages = {695--703},
doi = {10.1111/bcpt.13992}
}
EUVIMED